News | November 15, 2013

Aspirin Ineffective in 20 Percent of Heart Disease Patients

Study highlights importance of measuring thromboxane biomarker to determine aspirin response

antiplatelet therapy clinical trial blood test platelet function corgenix
November 15, 2013 — A study conducted in Ireland found that aspirin does not adequately protect 20 percent of patients with established heart disease. Corgenix Medical Corp., developer of the AspirinWorks Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.
“These and other major trials have established that the failure of patients to respond to the intended beneficial effect of aspirin may be a key factor in putting millions at increased risk of heart attack and stroke,” said Douglass Simpson, president and CEO, Corgenix. “The AspirinWorks Test accurately measures thromboxane levels in healthy individuals, allowing physicians to identify its potential interference with aspirin’s ability to help reduce heart attack and stroke risk.”
The Irish study conducted by the Irish Heart Foundation’s National Cardiovascular and Stroke Research Network (NCSRN) prospectively evaluated aspirin response in 700 patients with stable coronary artery disease (CAD) by measuring thromboxane levels. Results showed that age, high blood pressure, weight and alcohol consumption were significant risk factors for a poor response to aspirin. Full study results were presented at the 64th Irish Cardiac Society Annual Scientific Meeting in Killarney, Ireland.
AspirinWorks is the only U.S. Food and Drug Administration (FDA)-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. The test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin.
For more information:,,

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init